Personalis, Inc. (PSNL)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Personalis, Inc. (PSNL)
Company Performance

Current Price

as of Oct 16, 2024

$4.78

P/E Ratio

N/A

Market Cap

$253.7M

Description

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Metrics

Overview

  • HQFremont, CA
  • SectorHealth Services
  • IndustryMedical/Nursing Services
  • TickerPSNL
  • Price$4.78-1.85%

Trading Information

  • Market Cap$253.70M
  • Float59.52%
  • Average Daily Volume (1m)681,627
  • Average Daily Volume (3m)1,475,566
  • EPS-$1.63

Company

  • Revenue$80.03M
  • Rev Growth (1yr)35.22%
  • Net Income-$12.80M
  • Gross Margin35.59%
  • EBITDA Margin-62.40%
  • EBITDA-$14.09M
  • EV$20.99M
  • EV/Revenue0.26
  • P/EN/A
  • P/S3.13
  • P/B2.26
Documents
SEC Filings
8-K (2024-09-19)
8-K (2024-08-16)
8-K (2024-08-07)
8-K (2024-06-27)
8-K (2024-05-21)
8-K (2024-05-08)
8-K (2024-02-28)
8-K (2024-01-05)
8-K (2023-12-05)
8-K (2023-12-01)
8-K (2023-11-28)
8-K (2023-11-07)
8-K (2023-08-28)
8-K (2023-08-08)
8-K (2023-06-14)
8-K (2023-06-09)
8-K (2023-05-19)
8-K (2023-05-03)
8-K (2023-03-08)
8-K (2023-02-23)
8-K (2023-01-18)
8-K (2023-01-04)
10-Q (2024-08-07)
10-Q (2024-05-08)
10-Q (2023-11-07)
10-Q (2023-08-08)
10-Q (2023-05-03)
10-K (2024-02-28)
10-K (2023-02-23)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-07)
Earnings Report (2023-08-08)
Factset
Factset Business Description
Factset Street Account
Personalis reports Q3 EPS ($0.60) vs FactSet ($0.52) [6 est, ($0.54)-(0.48)] ($0.99, 0.00) (2023-11-07T21:04:14Z)
Personalis discloses workforce reduction of up to 65 employees - 8-K ($1.47, 0.00) (2023-12-01T21:58:47Z)
Personalis and Tempus enter into a strategic collaboration to advance cancer testing ($1.65, 0.00) (2023-11-28T21:17:48Z)